NEOADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCER


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

A number of international clinical trials involving Russian oncological centers have justified broad prospects for dual blockade of HER2-positive breast cancer as the metastatic process and during neoadjuvant therapy including anthracyclines and taxanes in combination with pertuzumab and trastuzumab. The antitumor activity of the Russian combined drug «pertuzumab+trastuzumab» (Beyodim) is confirmed by increase in relapse-free and overall survival.

全文:

受限制的访问

作者简介

V. Semiglazov

FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPH

Email: vsemiglazov@mail.iu
MD, Prof., Honored Scientist, Corresponding Member of RAS, Head of the Scientific Department of Bieast Tumors, Chief Researcher St.-Petersburg

V. Semiglazov

St. Petersburg State Medical University n.a. Acad. I.P. Pavlov of RMPH

St.-Petersburg

G. Dashyan

FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPH

St.-Petersburg

P. Krivorotko

FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPH

St.-Petersburg

K. Nikolaev

FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPH

St.-Petersburg

T. Semiglazova

FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPH

St.-Petersburg

A. Komyakhov

St. Petersburg State Medical University n.a. Acad. I.P. Pavlov of RMPH

St.-Petersburg

A. Bessonov

FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPH

St.-Petersburg

R. Donskikh

FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPH

St.-Petersburg

R. Paltuev

FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPH

St.-Petersburg

K. Zernov

FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPH

St.-Petersburg

参考

  1. Семиглазов В.Ф., Семиглазов В.В. Рак молочной железы: биология, местное и системное лечение. М, 2014. 352 с.
  2. Cortazar P., Zhang L., Untch M., Mehta K., Costantino J.P., Wolmark N., Bonnefoi H., Cameron D., Gianni L., Valagussa P., Swain S.M., Prowell T., Loibl S., Wickerham D.L., Bogaerts J., Baselga J., Perou C., Blumenthal G., Blohmer J., Mamounas E.P., Bergh J., Semiglazov V., Justice R., Eidtmann H., Paik S., Piccart M.,Sridhara R., Fasching P.A., Slaets L., Tang S., Gerber B., Geyer C.E. Jr, Pazdur R., Ditsch N., Rastogi P., Eiermann W., von Minckwitz G. Pathological complete response and long term clinical benefit in breast cancer: the CTNEOBC pooled analysis. Lancet. 2014;384: 164-72.
  3. Rastogi P., Anderson S.J., Bear H.D., Geyer C.E., Kahlenberg M.S., Robidoux A., Margolese R.G., Hoehn J.L., Vogel V.G., Dakhil S.R., Tamkus D., King K.M.,PajonE.R, WrightM.J.,RobertJ.,PaikS, Mamounas E.P., Wolmark N. Preoperative chemotherapy updates of National Surgical Adjuvant Breast and Bowel Project Protocol B-18 and B-27. J. Clin. Oncol. 2008;26:778-85.
  4. Gianni L., Eiermann W., Semiglazov V., Manikhas A., Lluch A., Tjulandin S., Zambetti M., Vazquez F., Byakhow M., Lichinitser M., Cli-ment M.A., Ciruelos E., Ojeda B., Mansutti M., Bozhok A., Baronio R., Feyereislova A., Barton C., Valagussa P., Baselga J. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010; 375:377-84.
  5. Semiglazov V., Eiermann W., Zambetti M., Manikhas A., Bozhok A., Lluch A., Tjulandin S., Sabadell M.D., Caballero A., Valagussa P., Baselga J., Gianni L. Surgery following neoadjuvant therapy in patients with HER2 - positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study. Eur J Surg Oncol. 2011;37(10):856-63.
  6. Gianni L., Pienkowski T., Im Y.H., Roman L., Tseng L.M., Liu M.C., Lluch A., Staroslawska E., de la Haba-Rodriguez J., Im S.A., Pedrini J.L., Poirier B., Morandi P., Semiglazov V., Srimuninnimit V., Bianchi G., Szado T., Ratnayake J., Ross G., Valagussa P. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 13:25-32.
  7. U.S. Food and Drug Administration. FDA approves Perjeta for neoadjuvant breast cancer treatment. http://www. fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm370393. htm. Accessed March 3, 2015.
  8. Gradishar W.J., Anderson B.O., Blair S.L., Burstein H.J., Cyr A., Elias A.D., Farrar W.B., Forero A., Giordano S.H., Goldstein L.J., Hayes D.F., Hudis C.A., Isakoff S.J., Ljung B.M., Marcom P.K., Mayer I.A., McCormick B., Miller R.S., Pegram M., Pierce L.J., Reed E.C., Salerno K.E., Schwartzberg L.S., Smith M.L., Soliman H., Somlo G., Ward J.H., Wolff A.C., Zellars R., Shead D.A., Kumar R.; National Comprehensive Cancer Network Breast Cancer Panel. Breast Cancer Version 3. J. Natl. Compr. Canc. Netw. 2015;13(4):448-75.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2016